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Abstract
Protein phosphorylation participates in the regulation of all fundamental biological processes, and protein kinases
have been intensively studied. However, while the focus was on catalytic activities, accumulating evidence
suggests that non-catalytic properties of protein kinases are essential, and in some cases even sufficient for their
functions. These non-catalytic functions include the scaffolding of protein complexes, the competition for protein
interactions, allosteric effects on other enzymes, subcellular targeting, and DNA binding. This rich repertoire often is
used to coordinate phosphorylation events and enhance the specificity of substrate phosphorylation, but also can
adopt functions that do not rely on kinase activity. Here, we discuss such kinase independent functions of protein
and lipid kinases focussing on kinases that play a role in the regulation of cell proliferation, differentiation,
apoptosis, and motility.
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Introduction
Kinases are conserved during evolution. Orthologs with
‘kinase domains’ (so-called protein kinase-like folds; PKL)
are found in all three domains of life, [1]. Interestingly,
comparing the ‘kinomes’ from nematodes, insects, and
vertebrates a surprising number of kinases are shared. In
eukaryotes, the protein kinase family is one of the largest
gene families, counting for about 2% of all genes. The
human genome contains 518 putative protein and lipid
kinases. Based on sequence similarities they can be divided
into 9 groups of conventional kinases, which feature a
typical kinase domain sequence, and 8 small groups of
unconventional kinases, which lack typical kinase domain
sequences but reportedly possess biochemical kinase activ-
ity [2,3]. Almost half of the human kinases can be mapped
to known disease loci, cancer amplicons, and mutations or
their deregulation can be directly correlated to human dis-
ease. Therefore, it comes as no surprise that kinases are
intensively studied, and kinase inhibitors have now a firm
place in the pharmaceutical armoury.
The importance of protein phosphorylation is under-
lined by a Nobel Prize in Physiology or Medicine awarded
to Edmond H. Fischer and Edwin G. Krebs in 1992
“for their discoveries concerning reversible protein phos-
phorylation as a biological regulatory mechanism”.T h e i r
key discovery about 55 years ago was that the conversion
of the inactive enzyme phosphorylase b to the active phos-
phorylase a is caused by phosphorylation, and that the
conversion factor is a protein kinase, phosphorylase kinase
[4,5]. That breakthrough has established a firm role for
protein kinases in the regulation of diverse fundamental
cellular processes and spawned an immensely fruitful field
of kinase research. At the same time this success, however,
has blinkered us to solely concentrate on the catalytic
activities of kinases neglecting other functions of these
proteins, which do not require the phosphotransferase
activity.
Early examples of non-catalytic functions of protein
kinases were discovered in yeast. In 1997 Posas and
Saito showed that the yeast Pbs2p protein can serve
both as a scaffolding protein and a protein kinase [6].
The adaptation of the yeast S. cerevisiae to high osmo-
larity is regulated by two independent pathways, which
both contain a three-tiered cascade of kinases. In one of
these pathways Pbs2p serves as a bona fide kinase
(MAPKK), which links signalling from SSK2/SSK22 (a
MAPKKK) to HOG1 (a MAPK). In the other pathway
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assembling a complex of Sho1p, Ste11p, and Hog1p pro-
t e i n sa n da tt h es a m et i m ep r o v i d i n gt h ek i n a s el i n k
between Ste11p and Hog1p (Figure 1A). In another
example from budding yeast, Madhani and colleagues
showed in 1997 that the MAPK Kss1 has important
non-catalytic functions [7]. Non-phosphorylated Kss1
inhibits filamentation and haploid invasion through the
kinase independent inhibition of the Ste12-Tec1 tran-
scription factor complex. Phosphorylation by Ste7 (a
MAPKK) activates Kss1 catalytic activity and converts Kss1
from a repressor of filamentation into an activator. This
second function of Kss1 requires its kinase activity, which
acts to stimulate the Ste12-Tec1 complex (Figure 1B).
Although these discoveries are not only early but still
some of the clearest examples for a dual function of pro-
tein kinases, this new conceptual view did not gain trac-
tion until the last few years where a flurry of other
examples began to emerge and are now receiving sharply
increasing attention.
This review presents a synopsis of protein kinase func-
tions that are independent of catalytic activity, with a
special focus on kinases involved in the regulation of prolif-
eration, apoptosis, differentiation, cell adhesion and migra-
tion. A comprehensive summary is given in Table 1. Due to
space constraints we do not discuss the functions of pseu-
dokinases, but only review recent results suggesting that in
some cases their catalytic activities have developed to
become highly specialized rather than being lost.
Receptor Tyrosine Kinases (RTK)
Receptor Tyrosine Kinases (RTK) comprise a family of
about 60 cell surface receptors, which act as docking
platforms for polypeptide-based growth factors, cyto-
kines, and hormones [8]. RTKs are starting points for
several signalling pathways, and hence are not only key
regulators of many normal cellular processes, but also
play a major role in development and progression of
many malignancies [9]. Among the 60 receptors of the
RTK family, several family members are involved in
mechanisms where no kinase activity is required.
The Epidermal Growth Factor Receptor (EGFR/ERBB1) ERBB
family
The ERBB family of RTKs is one of the best known and
most extensively studied signal transduction networks with
implications ranging from cell division to cell death and
motility to cellular adhesion (extensively reviewed in
[10,11]). The receptor family consists of 4 members:
ERBB1 (also known as HER1 or EGFR), ERBB2 (also
known as HER2/neu), ERBB3 (HER3), and ERBB4 (HER4),
which can form homo- and heterodimers with specific
functions. 11 specific ligands are known to bind and acti-
vate ERBB receptors, which are the starting points of
downstream signalling pathways such as MAPK, AKT and
JNK signalling cascades [12].
The EGFR is activated by binding of several ligands,
including epidermal growth factor (EGF) and transforming
growth factor alpha (TGFa). EGFR forms homodimers as
well as three functional heterodimers with the other mem-
bers of the ERBB family, which stimulates its intrinsic
intracellular protein-tyrosine kinase activity and results in
autophosphorylation of several tyrosine residues in the C-
terminal domain of EGFR [13]. These phospho-tyrosines
serve as docking sites for an array of signal transducers
[14], including kinases, phosphatases, transcription factors,
and several adaptor proteins such as GRB2 and Shc, which
are responsible for the initiation of multiple downstream
signalling pathways. With this functional repertoire, it
comes as no surprise, that deregulation of expression
levels, gene amplifications and mutations of the EGFR or
Figure 1 Examples of catalytic-independent functions in yeast. (A) T h ed u a lr o l eo fP B S 2a ss c a f f o l da n dk i n a s ei ny e a s to s m o - s e n s i n g
pathways. (B) Antagonistic functions of the kinase Kss1 in filamentation and invasion.
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Kinase
Group
Protein Notes Organism References
Receptor
Tyrosine
Kinases
EGFR Mitogen-activated protein kinase stimulation by a tyrosine kinase-
negative epidermal growth factor receptor
CHO (Chinese hamster
ovary) cells
[21]
Tyrosine phosphorylation of mitogen-activated protein kinase in cells
with tyrosine kinase-negative epidermal growth factor receptors
B82L cells (mouse) [19]
EGFR-ERBB2 oligomers activate ERK and Akt, independent of EGFR
kinase activity
human [24]
Kinase-negative EGFR retains the capacity to stimulate DNA synthesis CHO cell line
(hamster)
[20]
No kinase activity of EGFR is required for activation of c-fos expression mouse [23]
Kinase-independent EGFR prevents autophagic cell death by
maintaining intracellular glucose level through interaction and
stabilization of the sodium/glucose cotransporter 1 (SGLT1).
human [16]
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial
translocalization of PUMA and PUMA-mediated apoptosis independent
of EGFR kinase activity. This function of EGFR/EGFRvIII leads to tumor
drug resistance of glioblastoma.
human [25]
ApTrkl Aplysia Trk-like receptor (ApTrkl), a Trk-like receptor in Aplysia sensory
neurons, was shown to have two modes of receptor internalization:
kinase activity-dependent internalization and serotonin-dependent,
kinase activity-independent internalization
mouse [213]
Insulin Receptor Unliganded insulin- and IGF-1 receptors exert a permissive effect on
cell death
Mouse adipocytes [214]
Induces phosphorylation and activation of phosphatase PHLPP1, a
negative regulator of Akt2 activity
[215]
Insulin-Like Growth
Factor I (IGF-1)
Receptor
Mediates Erk1/2 phosphorylation in a tyrosine phosphorylation
independent manner.
Smooth muscle cells [34]
EphA2 Some of EphA2 functions in cell motility, invasion and bone formation
are kinase-independent
[216]
EphA4/SEK1 Kinase-dependent and kinase-independent functions of EphA4
receptors in major axon tract formation in vivo
mouse [217]
EphA8 Overexpression of EphA8 enhances cell attachment to fibronectin [218]
EphB/NUK Kinase independent function of EphB receptors in retinal axon path
finding to the optic disc from dorsal but not ventral retina
mouse [219]
Kinase-Independent Requirement of EphB2 Receptors in Hippocampal
Synaptic Plasticity
mouse [220]
EphB2 regulates positioning of differentiated Paneth cells in small
intestine independently of kinase activity
intestinal epithelium [221]
EphB3 EphB3 is overexpressed in non-small-cell lung cancer and promotes
tumor metastasis in a kinase-independent manner.
Lung [222]
Overexpression of wild type or kinase dead protein decreases Cdc42/
Rac activity and reduces cell migration.
[223]
EphA3 In the absence of ephrin interaction, kinase-dead EphA3 recruits other
Eph molecules for oligomerization
human [224,225]
VAB-1 VAB-1, a C. elegans Eph receptor, regulates embryonic development
by kinase-dependent and -independent functions
C. elegans [226-228]
c-kit Complex formation with granulocyte macrophage colony-stimulating
factor (GM-CSF) receptor.
[229]
Non-receptor
Tyrosine
kinases
Src Overexpresion of non-catalytic domains of Src alters focal adhesion
properties
[107]
c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a
kinase-independent mechanism
mouse [109]
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Activation of the Src-dependent adaptor protein pp130cas in
fibroblasts in response to fibronectin binding does not require intrinsic
Src kinase activity
mouse [110]
Kinase-deficient Src protects src-/- mice against osteopetrosis. mouse [112]
Src mediates B cell antigen Receptor response [230]
Src mediates FAK phosphorylation at several tyrosine residues
independently of its kinase activity
KM12C (Human colon
cancer)
[111]
Src regulates Jak2/Stat5 activation induced by prolactin in mammary
tissue in a kinase-independent manner
[113]
Brk Brk (PTK6) promotes breast carcinoma cell proliferation [231]
FRK-1 Fer-related kinase-1 (FRK-1) performs a kinase-independent function in
differentiation and morphogenesis of the C. elegans epidermis during
embryogenesis.
Caenorhabditis
elegans
[232]
Lck Kinase-independent function of Lck in potentiating antigen-specific T
cell activation
human [114]
Hck The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-
independent Mechanism and Phosphorylates the Grb2-binding Site of
Bcr-Abl
COS7 cells [233]
Lyn Negative regulation of B cell Ag receptor (BCR) induced activation of
Protein Kinase C (PKC)
Chicken B cells [115]
Lyn increases p53 levels and stimulates p53-mediated transcription by
a kinase-independent mechanism
[234]
c-Abl Promotes p53 DNA binding [235]
Negatively regulates UV damaged DNA repair by recruiting CAL-4A
ubiquitin ligase
[236]
c-Abl promotes proteolytic destruction of damaged DNA binding
proteins in a kinase-independent manner
mouse [236]
Abl proper subcellular localization is correlated with its kinase-
independent activity
Drosophila [237]
FAK (Protein
Tyrosine Kinase 2)
FAK initiates endothelial cell development during embryogenesis Mouse endothelial
cells
[124]
FAK promotes cell survival by enhancing p53 degradation Mouse fibroblasts and
human cell lines
[126]
Mediates JNK activation in a kinase-independent manner by recruiting
paxillin to the plasma membrane
[118]
Pyk2 (Protein
Tyrosine Kinase 2 B)
Pyk2 facilitates cell growth and survival by limiting p53 levels MEF and cell lines [128]
ACK (TNK2) The scaffold function of ACK, rather than kinase activity, seems
important in the context of cell growth control
human [238]
ACK2 Overexpressed ACK2 inhibits kinase activity of FAK and cell growth
independently of its kinase activity; however its ability to dissolve actin
stress fibers and to disassemble focal complexes requires kinase
activity
NIH3T3 cell line [239]
BMX Bone Marrow Kinase (BMX) regulates inflammation in rheumatoid
arthritis
mouse [240]
Itk Itk mediates antigen receptor induced activation of transcription factor
SRF (Serum Response Factor) independently of its kinase activity
DT40 chicken B cells [241]
Itk regulates Vav localization and T cell Receptor-induced actin
polarization independently of its kinase activity.
T cells [242]
Zap-70 Whereas the kinase activity of Zap-70 is required for signal
transduction downstream to the T cell antigen receptor (TCR), this
protein has kinase-independent functions in activating small G protein
Rap1, required for integrin-mediated adhesion.
T cells [243]
TKL TbRI TGFb receptor recruits and activates TAK1 via interaction with TRAF6 human [244]
Raf-1 Raf-1 binds to and inhibits ROK-alpha kinase activity MEF [66]
Raf-1 plays an essential, kinase-independent function as a spatial
regulator of Rho downstream signaling during migration.
MEF [65]
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Raf-1 sets the threshold of Fas sensitivity by modulating ROK-a
signaling
MEF [64]
Raf-1:ROK-alpha complex linked to STAT3/Myc activation is crucial for
cell fate decisions in Ras-induced tumorigenesis.
mouse [67]
Raf-1 binds and inhibits the pro-apoptotic kinase MST2 human and mouse
cell lines
[68-70,245]
Raf-1 binds and inhibits the pro-apoptotic kinase ASK1 mouse [246]
Cardiac-specific disruption of the Raf-1 gene induces cardiac
dysfunction and apoptosis
mouse [75]
Raf-1 promotes cell survival by antagonizing apoptosis signal-
regulating kinase 1 through a MEK-ERK independent mechanism
human [74]
MEK kinase activity of Raf-1 is not essential for function and normal
mouse development. Raf-1 plays a role in preventing apoptosis.
mouse [43,44]
A-Raf A-Raf binds and inhibits the pro-apoptotic kinase MST2 human [71,72]
Raf-1/B-Raf Regulation and role of Raf-1/B-Raf heterodimerization human [51,53]
Mixed-lineage kinase 3 (MLK3) regulates B-Raf through maintenance of
the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor
protein
human [55]
Diacylglycerol Kinase h Augments C-Raf Activity and
B-Raf/C-Raf Heterodimerization
human [56]
PKK Protein kinase C-associated kinase (PKK, also known as RIP4/DIK)
lacking kinase activity can induce partial activation of NFB
[247]
CMGC ERK ERK (Extracellular signal-regulated kinase) acts as a transcriptional
repressor for interferon gamma-induced genes.
human [89]
Catalytic Activation of the Phosphatase MKP-3 by ERK2 Mitogen-
Activated Protein Kinase
human [86]
ERK Activates Topoisomerase IIalpha through a Mechanism
Independent of Phosphorylation
mouse, human [84]
ERK1/2 MAP kinases promote cell cycle entry by rapid, kinase-
independent disruption of retinoblastoma-lamin A complexes.
human [91]
PARP-1 usually gets activated by DNA strand breaks and is required for
DNA repair. ERK2 activates PARP-1 independently of DNA strand
breaks
rat [85]
ERK3 ERK3, an atypical member of the MAPK family, interacts with MAPK-
activated protein kinase 5 (MK5 or PRAK) independent of ERK3
enzymatic activity. Erk3 regulates MK5 cellular localization and
activation thus being involved in embryonic development.
mouse [248]
ERK5/Mpk1 Erk5, a member of the MAPK family, associates with the Paf1 complex
thereby blocking Sen1-mediated premature transcription termination.
yeast, human [249]
Erk8 Erk8 negatively regulates transcriptional co-activation of androgen
receptor and GRalpha by Hic-5 in a kinase-independent manner
[250]
p38 MAPK p38 inhibits cell cycle progression in a kinase-independent fashion,
whereas promotes G2/M checkpoint in a kinase-dependent manner
Several human and
murine cell lines
[98]
p38 blocks transcription in proliferating cells by sequestering
transcription co-activator Mirk/Dyrk1B
NIH3T3/human cell
lines
[99]
Cdc2 Cdc2 blocks cell cycle in S phase via inhibition of E2F Drosophila [251]
Cdk1/cdc28 Cdk1/cdc28 recruits proteosomes to coding region to maintain
transcriptional activity
yeast [252]
Cdk5 Cdk5 is a cell cycle suppressor in normal post-mitotic neurons Mouse primary
neurons
[253]
CK1 Casein Kinase 1ε Casein Kinase 1ε regulates Fz/planar cell polarity (PCP) pathway in
Drosophila development in a kinase-independent manner, whereas
Wnt-Frizzled (Fz)/beta-catenin pathway requires its kinase activity
Drosophila [254]
VRK-3 Vaccinia-related kinase 3 (VRK-3), a member of the VRK family,
suppresses ERK activity through direct binding to the MAPK
phosphatase Vaccinia H1-related (VHR). VHR is known to
dephosphorylate and inactivate ERK in the nucleus.
[255]
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CAMK AMPK AMP-activated protein kinase a (AMPKa) acts as transcriptional co-
activator of PPAR under ATP deprivation
Rat hepatocytes [256]
MARK2 MARK2 regulates neuronal morphology independently of kinase
activity
Neuronal cells [257]
DAPK Death-associated protein kinase (DAPK) increases glycolytic rate
through binding and activation of pyruvate kinase
[258]
STE MEK5 A constitutively active form of MEK5 is able to inhibit SUMOylation of
the atypical MAPK ERK5 independent of kinase activity, but dependent
on MEK5-ERK5 association
mouse [259]
MEKK1 The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and
mediates ubiquitination and degradation of ERK1/2
human [260]
PAK1 (p21-activated
kinase1)
Recruits Akt to the plasma membrane and facilitates Akt1 and PDK1
interaction
Cell lines including
Cos and NIH 3T3
[136]
Overexpressed PAK1 induced lamellipodia formation and membrane
ruffling independently of its catalytic activity
REF52 cell line [133]
PAK1 targeted to the plasma membrane promotes cell differentiation
in the PC12 model independently of its kinase activity
PC12 [132]
Overexpressed PAK promotes F-actin accumulation in a kinase
independent manner, whereas its effect on cell shape is kinase-
dependent
Swiss 3T3 [134]
PAK1 promotes formation of multiprotein complex in focal adhesions
that consists of PAK-PIX-PKL-Paxillin. Conformational change, but not
kinase activity of PAK1 is required for complex formation
CHO cells [135]
PAK1 induces activation of exchange factor, PIX, upon binding Gbg.
This leads to Cdc42 activation and subsequently PAK1 kinase
activation.
Myeloid cells [137]
PAK2 PAK2 controls spindle orientation independently of its kinase activity HeLa cells [139]
PAK4 PAK4 mediates TNFa-induced cell survival by promoting recruitment
of TRADD to TNFa receptor
HeLa cells [149]
PAK4 promotes cell survival by inhibiting caspase activation Human (HeLa cells)
and mouse (NIH3T3)
[148,261]
ASK1
(MAP3K5)
ASK1 inhibits NF-B-induced cell survival by perturbing TRAF6-TAK1
interaction
HEK293 [80]
ASK1 induces a Daxx-dependent caspase-independent cell death [78]
MST1 MST1 serine-threonine kinase, a component of the RASSF1-LATS tumor
suppressor network, binds androgen receptor (AR), but the kinase
activity of MST1 is not involved in inhibition of AR.
human, mouse [262]
AGC PDK1 Interacts with Ral-GDS and induces its GEF activity of in PI3 kinase
dependent manner
[182]
Forms a multiprotein complex, required for NFkB activation upon TCR
activation in T cells
[181]
Gprk2/GRK2 G protein-coupled receptor kinase 2 (Gprk2) promotes high-level
Hedgehog signaling by regulating the active state of Smo through
kinase-dependent and kinase-independent mechanisms in Drosophila
Drosophila [263]
Kinase activity-independent regulation of the cyclin pathway by GRK2
is essential for zebrafish early development.
Zebrafish [264]
Interaction assays of the neurokinin-1 (NK-1) receptor with G-protein
coupled receptor kinases (GRKs) reveal that GRK5 interaction with the
receptor was dependent on intact kinase-activity, whereas the high
affinity phase of GRK2 interaction was independent of kinase activity.
[265]
Gprk2 G Protein-coupled Receptor Kinase 2 (Gprk2) has kinase-independent
functions during Histamine H2 receptor desensitization
[266]
MSK2 Mitogen- and stress-activated protein kinase 2 (MSK2), a member of
the ribosomal S6 kinase (RSK) family, functions as an adaptor in
mediating activation of PKR (double-stranded RNA (dsRNA)-activated
protein kinase) independent of its catalytic activity.
human [267]
Atypical mTOR (FRAP) Differentiation of myoblasts can be rescued by Rapamycin-insensitive
or Rapamycin-insensitive kinase-dead mTOR
mouse [192]
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Dystrophin expression muscle cells mouse [195]
Negative regulation of microRNA-125b expression in skeletal muscles
during differentiation and muscle regeneration
Mouse [268]
Rad3 (ATR) Rad3 (ATR)-Rad26 (ATRIP) complex can recruit Tel1(ATM) to telomeres
independently of Rad3(ATR) kinase activity.
Fission yeast
(Schizosaccharomyces
pombe)
[269]
Tel1 ATM-related protein, Tel1, regulates telomere maintenance in yeast. Budding yeast
(Saccharomyces
cerevisiae)
[270]
H11 H11 has two functions in cardiac cells: At low doses, it induces
hypertrophy through kinase-independent activation of Akt, whereas at
high doses H11 causes apoptosis through protein kinase-dependent
mechanisms by inhibition of CK2.
mouse [271]
Other kinases Wnk With-no-lysine (K) kinases (Wnk) regulate ion transport via both
catalytic and non-catalytic mechanisms. While regulation of cation-
chloride-coupled cotransporters, Na+-K+-2Cl(-) cotransporter (NKCC) 1,
and NKCC2 by WNKs requires kinase activity, intersectin-mediated
endocytosis of ROMK1 is independent of Wnk kinase activity.
[272]
Wnk1 mediates activation of SGK1 downstream to the Insulin-like
growth factor 1.
[200]
WNK2 Tumor suppressor as indicated by preventing colony formation in
glioma cells
[273]
ILK ILK interaction with a-parvin but not its kinase activity is required for
embryonic development
Mouse [274]
ILK links the cytoskeleton and the plasma membrane at sites of
integrin-mediated adhesion.
Dosphila/C. Elegans [275,276]
ILK regulates actin reorganization in chondrocytes and modulates
chondrocyte growth independently of phosphorylation of Pkb/Akt and
GSK3-beta.
mouse [277]
ILK regulates cell polarization, adhesion and actin accumulation at the
integrin-adhesion sites
mouse [278]
ILK controls epidermis and hair follicle morphogenesis by modulating
integrin-mediated adhesion, actin reorganization, and plasma
membrane dynamics in keratinocytes
mouse [279]
IKKa IKKa controls epidermis formation via regulation of keratinocyte
differentiation in a NF-B-independent fashion
mouse [280]
IKKb Regulates vascular permeability and migration of endothelial cells by
regulating Akt activation.
Endothelial cells [281]
Aurora A/AIR-1 Aurora (AIR-1) stabilizes spindle microtubules independently of its
kinase activity, however kinase activity is required for centrosome
regulation
C. elegans [282]
TLK-1 Tousled-like kinase (TLK-1) mediates activation of Aurora B kinases
independently of kinase activity thus regulating cell division
Budding yeast
(Saccharomyces
cerevisiae)
[283]
Fa2p Fa2p, a member of the NIMA-family of kinases (Neks), regulates cell
cycle by associating with the proximal end of centrioles. While this cell
cycle function of Fa2p is kinase independent, its function of
coordinating of cilia is kinase dependent.
Chlamydomonas,
Kidney cells
[284]
Nek2B Nek2B, NIMA-related protein kinase, promotes assembly of a functional
zygotic centrosome independently of its kinase activity
Xenopus laevis [285]
Apg1/Atg1 In autophagic cells, Apg1 (Ulk-1 in human) kinase activity is required
only for Cvt trafficking of aminopeptidase I but not for import via
autophagy.
yeast [286]
Lipid kinases p110b The catalytic activity of p110b is dispensable for embryonic
development
Mouse [158]
DNA replication during the S phase [162]
Mediates double-strand DNA break repair via catalytic and non-
catalytic mechanisms
MEF and NIH 3T3 [161]
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Interestingly, in cancer tissues the expression level of
EGFR is correlated with prognosis, but not with respon-
siveness to EGFR inhibitor treatment [15]. This conun-
drum suggests that EGFR might contribute to tumor
progression independently of its kinase activity. Several
studies support this kinase-independent pro-survival
function of the EGFR.
First, loss of the kinase activity of the EGFR does not
produce phenotypes similar to the ablation of EGFR
protein expression [16]. While EGFR knockout animals
die soon after birth [17], animals expressing kinase-
defective EGFR are viable and display only some epithe-
lial defects [18].
Second, several groups reported the surprising results,
that a kinase-defective EGFR was capable to activate
downstream signalling (such as MAPK) and stimulate
DNA synthesis, while failing to induce the tyrosine phos-
phorylation of endogenous substrates in response to EGF
[19-22]. These kinase activity independent signalling
included transcriptional effects, as kinase-deficient EGFR
could activate c-fos expression [23]. The mechanism may
include heterodimerization with other ERBB members.
For instance, the co-expression of a kinase-inactive mutant
of EGFR (K721M) with ERBB2 resulted in EGF-dependent
Akt and MAPK activation., while kinase-inactive EGFR
alone was ineffective [24]. ERBB2’s kinase activity, but not
tyrosine phosphorylation, was required for this activation.
These results suggest that EGFR has catalytic-independent
functions, which might be achieved by heterodimerization
with other members of the ERBB receptor family.
More recent studies provide more mechanistic insights
as to the nature of kinase-independent signalling, which
relies on protein-protein interactions. In 2008, Weihua et
al. reported that EGFR, independently of its kinase activity,
prevents cancer cells from autophagic cell death by main-
taining the basal intracellular glucose level [16]. EGFR
interacts with and stabilizes the sodium/glucose cotran-
sporter (SGLT1) in order to promote glucose uptake into
cancer cells (Figure 2A). Interestingly, inhibition of the
EGFR kinase activity did not block this association with
SGLT1 or decrease basal intracellular glucose levels sug-
g e s t i n gt h a tn ok i n a s ea c t i v i t yi sr e q u i r e df o rt h i sr e g u l a -
tion. Similarly, the EGFR and its constitutively activated
variant EGFRvIII were shown to bind to and sequester the
proapoptotic Bcl-2 family member PUMA in the cyto-
plasm leading to tumour drug resistance [25] (Figure 2B).
These results have important implications for thera-
peutic approaches relying on agents that inhibit the
EGFR kinase activity, as the kinase independent functions
of EGFR may open escape routes, which for instance
maintain the viability of tumor cells even in the presence
of EGFR kinase inhibitors.
In addition to non-catalytic functions regulating
downstream effectors by the EGFR via direct protein
interactions, they also contribute to the regulation of
the localisation of the EGFR family itself. EGFR and
other ERBB receptors are known to be regulated by
endocytosis. Ligand binding induces the internalization
Table 1 Catalytic-independent kinase functions according to the 7 major kinase groups (Continued)
Endocytosis and oncogenic transformation as indicated by transferin
uptake and foci formation, respectively.
MEF [159]
p110g p110g regulates integrin activation in platelets and thrombus
formation in a kinase-independent manner; p110b contributes to the
same process by PIP3 production
Mouse [287]
Negatively regulates cardiac contractility by mediating
phosphodiesterase 3B activation and thus leading to cAMP destruction
Heart (mouse) [174]
p110gamma binds phosphodiesterase 3B, whereas the regulatory
subunit of PI3K, p87 binds Protein Kinase A (PKA). PKA, activated by
cAMP phosphorylates phosphodiesterase 3B and therefore leads to
negative regulation of cAMP levels in cardiomyocytes.
[176]
Protective role during myocardial ischemia and reperfusion injury Endothelial progenitor
cells (mouse)
[169]
Reparative neovascularisation after unilateral limb ischemia mouse [168]
p85 Positivey regulates JNK activation in a response to insulin stimulation brown adipose cells [288]
GTPase activity towards Rab4 and Rab5 small G proteins, as part of
negative PDGF regulation. Prevents cell transformation
[289]
p85 controls mammalian cytokinesis by regulating Cdc42 activation [290]
IP3K-A IP3K-A (Ins(1,4,5)P(3) 3-kinase-A) regulates cytoskeletal organization in a
kinase-independent manner
Lung epithelial cells
(H1299)
[291]
AGC - Containing PKA, PKG, PKC families; CAMK - Calcium/calmodulin-dependent protein kinase; CK1 - Casein kinase 1; CMGC - Containing CDK, MAPK, GSK3,
CLK families; STE - Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK - Tyrosine kinase (including receptor tyrosine kinases and non-receptor tyrosine
kinases); TKL - Tyrosine kinase-like. (adapted from [2])
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either targeted for ubiquitin-mediated degradation or
recycled back to the plasma membrane. While this pro-
cess was thought to require kinase activation, newer
data suggest that rather than EGFR kinase activity,
dimerization is necessary and sufficient for internaliza-
tion [26].
ERBB family receptors contain nuclear localisation sig-
nals [27] enabling them to translocate to the nucleus,
either as full length molecules (e.g. the EGFR) or as
fragments (e.g. ERBB4) after proteolytic processing [28]
(Figure 2C). Full-length EGFR trafficking from the
plasma membrane seems to involve the Sec61 translo-
con [29], where upon addition of EGF the cell surface
EGFR is trafficked to the endoplasmic reticulum. There,
the EGFR associates with Sec61b,a n di ss u b s e q u e n t l y
retrotranslocated from the ER to the cytoplasm. The
EGFR lacks a DNA binding domain, but can interact
with several transcription factors, such as STATs3/5 and
E2F1, to activate the expression of iNOS, COX-2,
MYBL2 (B-Myb), and AURKA (Aurora A) genes [28].
As the induction of target gene expression could be
inhibited by EGFR inhibitor drugs, gene transactivation
seems to require catalytic EGFR activity. However, it is
unclear whether kinase activity is needed for nuclear
translocation or the actual transcriptional transactivation
function of the nuclear EGFR. Interestingly, a C-term-
inal ERBB4 fragment lacking the kinase domain is able
to activate transcription by associating with the YAP2
transcription factor [30], suggesting that the transactiva-
tion function may be independent of catalytic activity.
Along these lines it has been suggested that the proteo-
lytic ERBB4 fragment serves as a chaperone for STAT5
[31] and YAP [32] that facilitates nuclear entry of these
transcription factors.
Kinase independent functions have been mainly
described for the ERBB family, but may be more wide-
spread in RTK signaling. This is not surprising given that
the function of RTKs relies heavily on their abilities to
assemble multi-protein signaling complexes. Although
the focus has been on proteins recruited to tyrosine
phosphorylation dependent docking sites, there is
increasing evidence that a great number of proteins are
associated with RTKs independently of ligand, and that
at least some of these proteins also participate in the reg-
ulation of signaling [33].
Insulin like Growth Factor-1 Receptor (IGFR)
Another recent example for kinase independent signaling
is the IGFR, which could stimulate the ERK pathway
despite having its kinase activity blocked by chemical
IGFR inhibitors or even abolished by mutation [34]. ERK
activation also was independent of PI3K kinase activity or
phosphorylation of IRS, which is a multivalent adaptor
protein that mediates many of IGFR downstream signaling
events. By contrast, ERK activation was blocked by chemi-
cal inhibition of Src family kinases or Gb/g subunits of
heterodimeric G-proteins, indicating that G-protein
coupled receptor signaling participates in the kinase inde-
pendent IGFR activation of ERK.
Kinase independent functions of Mitogen Activated
Protein Kinase (MAPK) pathway components
MAPK pathways are ubiquitous signaling modules con-
sisting of a three-tiered, and sometimes four-tiered, cas-
cade of kinases that is activated by a small G-protein as
input (Figure 3A). The name mitogen activated protein
kinase is historic, but now indicates a range of pathways
that respond to a variety of stimuli including mitogens,
hormones, and stress signals [35]. The activation of the
first kinase, MAPKKK, is initiated by it binding to an
Figure 2 Kinase actitvity-independent functions of the EGFR/ERBBs. (A) EGFR prevents autophagic cell death by stabilizing the sodium/
glucose cotransporter (SGLT1) thus maintaining the basal intracellular glucose level. (B) In glioblastomas, EGFR and EGFR vIII sequester the
proapoptotic Bcl-2 family member PUMA in the cytoplasm leading to tumour drug resistance. (C) EGFR and ERBB4 regulate gene expression by
direct interaction with transcription factors in the nucleus.
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phosphorylates and activates MAPKK, which are dual
specificity kinases that activate MAPK by phosphoryla-
tion of a tyrosine and threonine in the activation loop.
While signaling within the cascade is largely linear, the
terminal MAPK usually has a large number of substrates,
whose phosphorylation kinetics and localization contri-
bute to the generation of specific biological outputs
[35,36]. The design of MAPK modules conveys interest-
ing intrinsic properties, such as switchlike responses and
output stabilization [37,38].
Kinase independent functions of Raf kinases
Raf is the MAPKKK in the first MAPK pathway identified,
the Ras-Raf-MEK-ERK pathway. This cascade is a main
effector pathway of ERBB receptors, and altered in a high
percentage of cancers usually be mutation of Ras or
BRAFgenes. ERK features more than 150 substrates
thereby regulating many fundamental cellular functions,
including proliferation, differentiation, transformation,
apoptosis and metabolism [39].
Raf proteins come in three isoforms (A-Raf, Raf-1, B-
Raf) encoded by different genes. A wealth of experimen-
tal data suggests that MEK1 and MEK2 are the only
bona fide Raf substrates. B-Raf has the strongest kinase
activity towards MEK, while Raf-1 is weaker and A-Raf
activity is barely detectable [40]. From an evolutionary
point of view and phylogenetic comparisons, the single
Raf homologs in invertebrates (lin-45 in Caenorhabditis
elegans and D-Raf in Drosophila melanogaster)a r e
much closer related to B-Raf in terms of sequence, than
Raf-1 and A-Raf [41,42]. This suggests that B-Raf is the
archetypal MEK kinase, whereas A-Raf and Raf-1 may
have evolved towards MEK-independent functions.
Furthermore, gene ablation experiments in mice showed
that Raf-1 is required for survival and protects against
apoptosis [43,44]. Of note, reconstituting Raf-1
-/-mice
Figure 3 Kinase-independent functions of Raf kinases. (A) General structure of MAPK pathways. (B) Raf-1 controls cell migration and
differentiation by inhibiting the Rho effector kinase ROK-a. (C) Raf-1 controls TNF- and Fas-mediated apoptosis by inhibiting apoptosis signal-
regulating kinase-1 (ASK). (D) Raf-1 and A-Raf bind and inhibit the pro-apoptotic mammalian sterile 20-like kinase (MST2) thereby interfering with
its dimerization, autophosphorylation, and activation.
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activity fully rescued the apoptotic phenotype and pro-
duced viable mice [43]. Taken together, these results
suggested, that Raf-1 (and A-Raf) might possess kinase-
independent functions. During the hunt for new Raf tar-
gets, new kinase-independent roles for Raf proteins
besides the MEK substrate have emerged. These include
the regulation of cell motility and differentiation by con-
trolling the activity of ROK-a and the regulation of
apoptosis by suppressing the activity of the proapoptotic
kinases ASK1 and MST2, none of which requires Raf-1
kinase activity (reviewed in [45-47]).
Raf heteromers Over the years it emerged that Raf pro-
teins are able to homo- and heterodimerize with each
other [48-50]. Interestingly, these allosteric mechanisms
of dimerization regulate kinase activity of the complexes.
One intriguing phenomenon was that even a catalyti-
cally compromised B-Raf was capable of inducing kinase
activity of Raf-1 in trans in a manner dependent on a
physical interaction between B-Raf and Raf-1, suggesting
that the underlying mechanism is independent of a sim-
ple transautophosphorylation route [46,51-53]. Only
recently, the exact mechanism of how these dimers are
regulated was discovered [54], which suggests that two
Raf proteins are found in a ‘side-to-side’ dimer config-
uration. Several proteins seem to be responsible for the
correct configuration, which include the scaffold KSR
and 14-3-3 proteins [54]. Additionally, two kinases,
MLK3 and DGKh can enhance and maintain Raf-1/B-
Raf heterodimer formation independently of their kinase
activity [55,56]. What has not been solved yet is the
mechanism how a kinase dead Raf protein can stimulate
the activity of another Raf protein in the context of a
heterodimer, but an allosteric mechanism is the most
plausible possibility. The observation that Raf-1 activa-
tion by heterodimerization with B-Raf seems to proceed
differently from the activation used by growth factors
[51], is in keeping with such an alternative mechanism
of Raf activation exerted by allosteric changes. Interest-
ingly, Raf-1 and B-Raf also can induce allosteric confor-
mation changes in KSR, which conveys KSR the ability
to phosphorylate MEK [57,58]. KSR is scaffolding pro-
tein that binds Raf, MEK and ERK, but whether KSR
also has kinase function is controversial with most evi-
dence indicating that at least mammalian KSR proteins
lack kinase activity [59]. Although, in vitro MEK phos-
phorylation by KSR is weak and mainly occurs on sites
different from the known activating sites [57], work with
KSR1 knockout cells has suggested that KSR1 is
required for efficient ERK pathway activation in cells
[58]. This enhancement may reflect allosteric coopera-
tivity between Raf and KSR, and maybe other MEK
kinases, when assembled into multi-protein complexes
in cells. This kind of complex formation may also play a
pathophysiological role in cancer. It could explain the
surprising finding that a small number of B-Raf muta-
tions occurring in tumors have reduced kinase activity,
and exert their oncogenic action by stimulating Raf-1
[52]. A therapeutically even more important observation
is that Raf inhibitory drugs can activate the ERK path-
way, and in clinical trials may be responsible for some
adverse side effects of otherwise highly efficacious Raf
inhibitors [60,61]. This paradoxical activation of ERK
occurs in tumor cells with Ras mutations, which coop-
erate with Raf inhibitors to induce B-Raf-Raf-1 heterodi-
merization [62]. As the Raf heterodimer activates MEK
at least 30-fold stronger than B-Raf, but only requires
o n eR a fp a r t n e rt oh a v ek i n a s ea c t i v i t y[ 5 3 ] ,e v e na
slightly incomplete inhibition of Raf will promote ERK
pathway activation by Raf heterodimers.
ROK-a ROK-a is a direct effector of the Rho GTPase,
which is activated by binding to active Rho [63]. In Raf-
1 knockout cells ROK-a is hyperactivated and misloca-
lized to the membrane [64,65]. Furthermore, Raf-1-
mediated inhibition of ROK-a promotes cell migration
and reduces sensitivity to Fas-induced apoptosis [64,65].
Stimulation with growth factors induces an interaction
between the regulatory region of Raf-1 and the kinase
domain of ROK-a, resulting in inhibition of ROK-a
kinase activity [66] (Figure 3B). This in trans regulation
of a kinase domain by the regulatory domain of another
kinase introduces a new concept of kinase regulation
that may have important implications for signal coordi-
nation where the activation of one pathway automati-
cally would inhibit another pathway. In a more recent
study, Raf-1-mediated inhibition of ROK-a was shown
to block keratinocyte differentiation, thus allowing both
the development and maintenance of Ras-driven epider-
mal tumors in mice [47,67]. Of interest, the regulation
of ROK-a by Raf-1 is exclusively mediated by protein-
protein interactions and does not require Raf-1 kinase
activity.
MST2 The other proapoptotic kinase, which is inhibited
by Raf-1, is mammalian sterile 20-like kinase, MST2,
which was identified in a proteomics screen of Raf-1-
associated proteins [68]. MST2 is activated by dimeriza-
tion and autophosphorylation of the activation loop.
Raf-1 interferes with MST2 dimerization and autopho-
sphorylation by binding to the MST2 SARAH domain,
which mediates MST2 dimerization (Figure 3D). Raf-1
kinase activity is not required for this regulation as
kinase-dead Raf-1 mutants, or even the mutant lacking
the complete kinase domain, also can inhibit MST2 acti-
vation. As a result, MST2 activity is constitutively ele-
vated in Raf-1 knockout cellsa n dh y p e r a c t i v a t a b l eb y
Fas stimulation or expression of RASSF1A [68,69].
Interestingly, the Raf-1-MST2 interaction is induced by
stress and relieved by mitogens. Upon stimulation of
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ERK pathway and promote proliferation, but at the
same time dissociates the MST2-Raf-1 complex and
promotes apoptosis [70]. Coupling cell proliferation to
the risk of cell death seems paradoxical at first sight, but
this dual role makes perfect sense for higher organisms
where the uncontrolled proliferation of cells can lead to
severe diseases including cancer. In a subsequent study,
we could show that A-Raf, the third member of the Raf
family, also binds to and inhibits MST2 [71,72]. Similar
to Raf-1, A-Raf kinase activity is not required as kinase-
dead A-Raf mutants also can inhibit MST2 activation.
However, while Raf-1 binding to MST2 is induced by
stress and reduced by mitogens, A-Raf binds to MST2
constitutively and seems to promote the survival of can-
cer cells by restraining MST2 mediated apoptosis [71].
B-Raf binds MST2 only very weakly [68]. Thus, the
observed differential MST2 binding pattern inversely
correlates with the kinase activity towards MEK and the
evolution of the Raf family. B-Raf as the oldest member
possesses the strongest MEK kinase activity and the
lowest affinity for MST2, while the youngest member,
A-Raf, has the poorest MEK kinase activity but the
strongest capacity to bind and inhibit MST2 [72]. This
observation suggests that during evolution the role of
Raf might have shifted from activating the ERK pathway
to inhibiting the MST2 pathway.
From a therapeutic point of view, targeting these cataly-
tic-independent Raf interactions (ROK-alpha, ASK1,
MST2) in cancer might prove to be a good strategy. Dis-
ruption of Raf-1/ROK-alpha might provoke the differen-
tiation of epidermal skin tumor cells, while the
dissociation of Raf-1/A-Raf from ASK1 and MST2 should
activate these kinases to cause apoptosis in tumor cells.
ASK1 Another kinase, which is regulated by Raf-1 inde-
pendent of its catalytic activity is apoptosis signal-regulat-
ing kinase-1 (ASK) (Figure 3C). ASK1 works as a
MAPKKK in the JNK and p38 MAPKs pathways to pro-
mote apoptosis induced by stress or by death receptors,
such as the TNF- receptor or Fas [73]. Raf-1 binds to
ASK1 inhibiting its kinase activity and apoptosis. Raf-1
catalytic activity was not required for the control of ASK1
as a kinase dead Raf-1 mutant inhibited ASK1 as potent as
wildtype Raf-1 [74]. Although the direct mechanism of
inhibition is not known yet, the pathophysiological rele-
vance of ASK1 inhibition by Raf-1 was demonstrated in a
mouse model of heart disease [75]. A tissue-specific
knockout of the Raf-1 gene in the heart muscle resulted in
ventricular dilation and fibrosis caused by an increase in
cardiomyocyte apoptosis. These pathological changes
could be prevented by also knocking out the ASK1 gene.
Interestingly, ASK1 is able to induce apoptosis in a
kinase activity dependent and independent manner. The
kinase dependent way executes apoptosis via the activation
of JNK and subsequent inactivation of Bcl-2 [76] and
stabilization c-Myc [77]. The kinase independent pathway
induces a caspase-independent form of cell death, which is
enhanced by the binding of ASK1 to Daxx [78]. The con-
tribution of this kinase independent pathway to ASK1
induced cell death still needs to be clarified, as it relied on
the overexpression of ASK1 or kinase defective mutants.
In addition, Daxx is an activator of the ASK1 kinase activ-
ity, and Daxx induced apoptosis was reported to be
blocked by a kinase deficient ASK1 mutant [79]. Another
potential target of kinase-independent ASK1-induced
apoptosis is the transcription factor nuclear factor-kappaB
(NFB), a key regulator of immune and inflammatory
responses that exerts anti-apoptotic roles in various cells.
ASK1 directly interacts with TAK1 (transforming growth
factor-beta-activated kinase 1), a kinase involved in NFB
activation in response to inflammatory and cytokine sig-
nalling. ASK1inhibits NFB activation by interfering with
the formation of the TRAF6/TAK1 complex that mediates
interleukin-1 induced TAK1 activation [80]. This disrup-
tion renders cells vulnerable to apoptosis upon inflamma-
tory stress.
ERK MAPK
ERK1 and ERK2 are the MAPKs at the end of this path-
way featuring more than 150 known substrates, and it is
still far from clear how these diverse functions are coordi-
nated in order to achieve the intended biological outcome
and specificity [39]. Besides their canonical kinase depen-
dent functions, both ERK kinases were shown to influence
their substrates not only by phosphorylation, but also by
direct protein-protein interactions independently of ERK
kinase activity [81-83]. There are only few examples, but
as ERK tends to associate with its substrates in rather
stable pre-activation complexes [36] this type of regulation
may be more widespread than currently appreciated.
One example is topoisomerase IIa, an enzyme involved
in winding and unwinding of DNA and therefore crucial
in replication and transcription. Shapiro and co-workers
reported that topoisomerase IIa is activated by ERK by a
phosphorylation-independent process [84]. The exact
mechanism of this activation is not clear. Interestingly, it
requires a double phosphorylated ERK protein that is in
the activated conformation, but it does not rely on ERK
kinase activity itself. ERK is likely to induce a conforma-
tional change of the topoisomerase by a direct interaction,
thus leading to the expected regular DNA unwinding
activity of the topoisomerase [84].
Another interesting kinase independent target of ERK2
is PolyADP-ribose polymerase 1 (PARP-1), where no
kinase activity of ERK is required. PARPs catalyze the
posttranslational modification of nuclear proteins by poly-
ADP-ribosylation. Usually, the catalytic activity of PARP-1
is stimulated by DNA strand breaks, and its activation is
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co-workers report an alternative mode of activation [85],
where ERK2 interacts with PARP-1 and activates it inde-
pendent of DNA strand breaks Figure 4B). Of note, these
findings indicate that while phosphorylation of ERK is
required for the interaction and activation of PARP-1, no
kinase activity of ERK2 is necessary for this process.
Another example is an enzyme that dephosphorylates
ERK, the phosphatase MKP3, which negatively regulates
ERK activation [86]. MKP3 directly interacts with ERK
through a region of the phosphatase termed kinase inter-
action motif (KIM). Interestingly, this interaction is inde-
pendent of the phosphorylation status of ERK and its
kinase activity, as phosphorylation of the activating resi-
dues of ERK does not induce a dissociation of the ERK-
MKP3 complex. However, this interaction enhances the
phosphatase activity of MKP3. In addition, MKP3 is a
mitogen induced gene and located in the cytosol [87].
These traits indicate that the association of MKP3 with
ERK also could be involved in a feedback regulation that
eventually shifts ERK activity to the nucleus. Thus,
MKP3 may not only function as inhibitor, but rather
shape spatiotemporal gradients of ERK activation. This
hypothesis needs further testing, but recent studies point
to an important role of MKPs to regulate spatiotemporal
aspects of ERK signaling [88].
Non-catalytic functions of ERK2 can be also linked with
interferon signaling [89]. ERK2 was surprisingly identified
in a large screen as a DNA-interacting protein. ERK bind-
ing to DNA was independent of kinase activity, direct, and
to a specific DNA sequence, GAAAC, found in the pro-
moters of interferon-g (INFg) responsive genes. This
sequence motif is also bound by the C/EBP-b transcription
factor, and ERK2 acted as a transcriptional repressor by
Figure 4 Catalytic-independent functions of MAPKs. (A) Topoisomerase IIa, involved in winding and unwinding of DNA, is activated by ERK
by a phosphorylation-independent process. (B) Activated ERK2 interacts with PolyADP-ribose polymerase 1 (PARP-1) and activates it
independent of ERK kinase activity and DNA strand breaks. (C) ERK can repress INFg induced genes by directly binding to a specific DNA
sequence and displacing the CEBP-b transcription factor. (D) Activated ERK1 and ERK2 regulate the cell cycle entry by dislodging Rb from its
interaction with lamin A. Rb is released to the nucleoplasm and is rapidly phosphorylated and inactivated, leading to activation of the
transcription factor E2F and cell cycle entry. (E) p38 inhibits cell cycle progression by blocking Mirk/Dyrk1B transcriptional activity in proliferating
cells.
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addition, kinase independent and dependent ERK func-
tions may collaborate to form autoregulatory feedback
l o o p s .I nt h ec a s eo fI N F g responsive genes, ERK can
repress their transcription by direct DNA binding. How-
ever, when ERK becomes activated it can phosphorylate
C/EBP-b which displaces ERK from the DNA and stimu-
lates gene transcription. The increase in nuclear ERK
caused by ERK activation eventually can dislodge C/EBP-b
from the promoter again and terminate transcription. The
transcriptional induction of MKPs, which deactivate ERK
by dephosphorylation, ensures that C/EBP-b activation by
ERK also ceases. This ability to regulate gene transcription
by direct DNA binding highly increases the number of
ERK targets.
This theme of competing for critical binding sites is reit-
erated in the context of cell cycle regulation by the ERK
pathway. ERK kinase activity is crucial for promoting cell
cycle entry by various mechanisms including the induction
of cyclin D1, stabilization of c-Myc and regulation of cell
cycle inhibitors such as p21
waf/cip and p27
kip[90]. A kinase
independent component was only recently discovered
[91]. Lamin A, an integral part of the nuclear matrix and
involved in the stabilization of chromatin structure and
regulation of gene expression, was shown to be a mutually
exclusive docking protein for ERK1/2 and the retinoblas-
toma (Rb) protein (Figure 4D). When ERK1/2 becomes
activated and enters the nucleus, ERK1/2 dislodges Rb
from its interaction with lamin A. Rb released to the
nucleoplasm is rapidly phosphorylated and inactivated,
leading to the activation of the transcription factor E2F
and cell cycle entry. No kinase activity from either ERK1
or ERK2 was necessary for these processes [91].
p38 MAPK
The mammalian p38 subfamily of MAPKs comprises 4
members (a, b, g and δ) that are differentially expressed in
various tissues, and activated in response to a wide range
of extracellular stress stimuli, including cytokines and
growth factors [92]. Numerous data obtained from mouse
knockout studies and selective pharmacological inhibitors
implicate an important role of p38a MAPK in inflamma-
tory and immune responses [93-95]. More recent studies
show that the mammalian p38 MAPK pathway behaves as
a cell cycle inhibitor in both G1/S and G2/M checkpoint
controls in response to stress stimuli [96,97]. Whereas the
role of p38 in cell cycle regulation was clearly established,
some of these functions may not require p38 catalytic
activity. For instance, p38a depletion, but not its specific
pharmacologic inhibition, impeded cell proliferation and
caused mitotic arrest, revealing p38a functions indepen-
dent of its kinase activity [98]. Moreover, these phenotypes
were reversed by the ectopic expression of a kinase-dead
p38a mutant. Finally, overexpression of wild type or
kinase-negative p38a also strongly inhibited cell prolifera-
tion, proving that p38a also has a key kinase-independent
function [98]. However, despite the clear absence of
requirement for p38 catalytic activity to regulate cell cycle
progression, the exact mechanism used to achieve this
function is unknown.
Mirk/Dyrk1B protein kinase is a potential candidate to
explain a kinase-independent role of p38 in cell cycle regu-
lation (Figure 4E). Mirk functions as a transcriptional acti-
vator of genes involved in the response to certain stress
agents [99]. Co-immunoprecipitation experiments demon-
strated that both wild type and kinase-inactive p38 bind to
Mirk and prevent its association with upstream activators
and transcriptional co-factors. Interestingly, this effect is
isoform specific, as only the p38a and p38b, but not the g
or δ isoforms, bind to Mirk. In addition, the observation
that Mirk protein levels were variable while p38 levels
stayed constant suggested that endogenous p38 could only
block Mirk function when Mirk levels were low (S phase)
and not when Mirk levels were elevated (G0/G1) [99].
These observations emphasized a novel cell cycle-depen-
dent function for p38, suppressing Mirk transcriptional
activity in a kinase-independent fashion only when cells
are proliferating.
Kinase independent functions in regulating cell adhesion
and migration Src
Src belongs to a family of eight non-receptor tyrosine
kinases and is implicated in a wide variety of signal trans-
duction pathways. Src proteins regulate many fundamental
cellular processes, such as proliferation, differentiation, cell
shape, migration and apoptosis [100-102]. These pleiotro-
pic functions of the Src family explain the importance of
these kinases within the signalling machinery, and it comes
as no surprise that most members of this family have been
identified as oncogenes [103]. Src proteins feature a modu-
lar structure of three domains, the N-terminal SH3
domain, the central SH2 domain and a tyrosine kinase
domain. The SH2 and SH3 domains cooperate in regulat-
ing the auto-inhibition of the kinase domain. Additionally,
an inhibitory tyrosine phosphorylation in the C-terminus
acts a binding site for the SH2 domain, which locks the
protein in a closed conformation, and further facilitates
binding of the SH3 domain to a linker region between the
SH2 and kinase domain. This architecture allows for multi-
ple mechanisms for c-Src activation, either by dephosphor-
ylation of the C-terminal tyrosine by protein tyrosine
phosphatases or competitive binding to the SH2 and SH3
domains by other proteins. The list of Src family kinase
substrates is long [104,105], but here we briefly discuss tar-
gets of Src, which are regulated in kinase independent way.
Activation of integrin signalling is associated with a
transient increase in Src kinase activity and translocation
of Src to the focal adhesion complex and subsequent
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[106-108]. Src-deficient fibroblasts were shown to have
defects in cell spreading which is presumably related to
the activation of Src by integrins. Complementation of
t h i sp h e n o t y p ed o e sn o tr e q u i r ek i n a s ea c t i v i t yo fS r c ,a s
cell spreading is restored by either wild type or kinase-
defective Src [109]. In a similar fashion, activation of the
Src-dependent adaptor protein pp130
CAS in fibroblasts in
response to fibronectin binding does not require Src
kinase activity [110]. Overexpression of Src in human
colon cancer cells induces FAK phosphorylation on
several tyrosine residues. Surprisingly, only one phos-
phorylation site requires the catalytic activity of Src,
whereas phosphorylation on four other sites requires the
intact SH2 domain of Src but not its catalytic activity
[111]. Ablation of both Src alleles in the mouse causes
osteopetrosis due to an intrinsic defect in osteoclasts
[112]. Surprisingly, re-expression of kinase-defective ver-
sion of c-Src led to a reduction in osteopetrosis in Src
-/-
animals and partially rescued a defect in cytoskeletal
organization observed in Src
-/- osteoclasts. These results
suggest that no kinase activity is required for this
phenotype.
These results suggest important kinase independent
functions of Src in integrin signalling and cytoskeletal
organization. This is not surprising given that they
strongly rely on spatial organization, which may be better
suited to be negotiated by protein interactions rather that
catalytic activities.
However, while cytoskeletal organization is the prime
paradigm for kinase independent Src family functions,
there is also evidence for kinase independent signalling in
other roles. These examples include the organisation of
multiprotein signalling complexes in signalling by cyto-
kines [113], the T-cell receptor [114], and the B-cell recep-
tor [115]. The evidence is sparse but consistent, suggesting
that we are far from having fathomed the kinase indepen-
dent functions of Src family kinases.
Focal Adhesion Kinase (FAK)
FAK is a tyrosine kinase mediating integrin signalling and
also participating in signal transduction by growth factor
receptors [116,117]. FAK contains an N-terminal FERM
(band 4.1, ezrin, radixin, moesin homology), a kinase and
a C-terminal FAT (focal adhesion targeting) domain. The
FAT domain links FAK to integrins and focal adhesions,
whereas the FERM domain connects FAK to membrane
growth factor receptors and is also responsible for nuclear
translocation. Early reports suggested that FAK could play
a scaffolding role mediating crosstalk between signalling
pathways. Indeed, FAK has been shown to induce ancho-
rage-dependent JNK activation in a kinase-independent
fashion by interacting with paxillin [118]. The exact
mechanism is not known but seems to rely on FAK pro-
moting paxillin localization to the cell membrane and the
recruitment of paxillin kinase linker (PKL) and PAK-Inter-
acting exchange Factor (PIX) [119], a guanine nucleotide-
exchange factor (GEF) that activates Rac, which in turn
activates the JNK pathway [120,121] (Figure 5A). Interest-
ingly, JNK phosphorylation of S178 in paxillin enhances
the binding of FAK to paxillin [122] creating a positive
feedback loop that could promote the accumulation of
paxillin at focal adhesions.
Importantly, FAK plays a crucial role in vascular devel-
opment, and mice lacking FAK in their vascular system
die before birth due to defects in angiogenesis and apopto-
sis of endothelial cells [123]. Mice expressing a kinase-
deficient FAK mutant selectively in endothelial cells still
died before birth, but the embryos survived longer than
animals without any FAK in their vascular system [124].
Expression of kinase-dead FAK did not correct the vessel
malformation, but enhanced endothelial cell survival by a
mechanism involving the downregulation of the cyclin-
dependent kinase inhibitor p21
waf/cip[124]. p21
waf/cip was
one of the first p53 target genes identified [125]. FAK inac-
tivation during mouse development results in p53- and
p21-dependent mesodermal cell growth arrest. By creating
FAK
-/-p21
-/- double knockout fibroblasts Lim et al. [126]
showed that FAK, in a kinase-independent fashion, causes
p53 instability via enhanced Mdm2-dependent p53 ubiqui-
tination (Figure 5B). p53 inactivation required the FAK
FERM domain for nuclear localization, p53 binding and
connections to Mdm2, the p53 specific ubiquitin ligase
responsible of p53 degradation. These observations
defined a scaffolding role for nuclear FAK in facilitating
cell survival through enhanced p53 degradation [126].
Pyk2 is a cytoplasmic tyrosine kinase related to FAK and
sharing similar domain structure. Interestingly, compensa-
tory Pyk2 expression was observed in FAK
-/- mice [127],
suggesting some redundancy between FAK and Pyk2 func-
tions. Indeed, FAK knockdown induced p53 activation and
cell cycle arrest in endothelial cells, but a subsequent
increase in Pyk2 expression led to p53 downregulation
and the release of cell cycle block [128]. Moreover, in
FAK
-/-p21
-/- double knockout mouse embryo fibroblasts,
an increase of p53 levels associated with inhibition of cell
proliferation was observed only when Pyk2 was downregu-
lated [128]. Thus, similar as FAK, Pyk2 promotes Mdm2-
dependent p53 ubiquitination to facilitate cell proliferation
and survival in a kinase-independent manner (Figure 5B).
PAK
p21-activated kinase 1 (PAK1) is a serine/threonine
kinase belonging to the highly homologous group I of
PAKs (PAKs 1-3). PAK1-3 activation is mediated by Rho
family small G proteins, including Rac and Cdc42, which
bind PAKs and induce its conformational change leading
to exposure and activation of the catalytic domain [129].
PAKs are associated with a wide variety is cellular func-
tions, including regulation of the MAPK pathway,
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nogenesis and tumor invasion [129-131]. Several early
studies demonstrated that PAKs have some kinase-inde-
pendent functions including cytoskeletal regulation and
differentiation [132-134]. On the molecular level, PAK
was demonstrated to coordinate the formation of a
multi-protein complex, which contains PAK, PIX, PKL
and Paxillin in focal adhesions (Figure 5C). This activity
required the conformational change of PAK, since acti-
vated Rac or Cdc42 were able to promote this effect
[135]. As described above, the scaffolding function of
FAK seems instrumental for recruiting paxillin and acti-
vating Rac via PKL and PIX (Figure 5B). Active Rac binds
PAK, which is not only a Rac effector but also interacts
with PIX, which in turn stimulates Rac. Thus, multiple
protein interactions coupled to positive feedback loops
that promote protein recruitment may by key to focal
adhesion formation and function by forming a temporally
dynamic yet physically stable platform.
While these studies referred to a scaffolding function of
the PAK N-terminal regulatory domain, later studies
pointed out new, kinase-independent functions of the C-
terminal PAK kinase domain [136,137]. A dual, kinase-
dependent and -independent role of PAK1 was demon-
strated in myeloid cell migration. Chemokine binding to
the G Protein Coupled Receptor (GPCR) induces a direct
interaction between Gbg and PAK1. This interaction
leads to activation of PIX and activation of Cdc42, which
in turn leads to activation of PAK, an event required for
the directional sensing of neutrophils [137]. The confor-
mational change of PAK1 induced by the Gbg binding
can prevent formation of PIX dimers, and therefore facili-
tate its GEF activity towards Cdc42 [137,138]. In this sys-
tem, PAK1 mediates activation of its own catalytic
activity, thus forming a positive feedback loop [137] (Fig-
ure 5D). In general, PAK1’s ability to function as a scaf-
fold for the GEFs that activates the GTPases, which
activate PAK1, seems to generate an organising principle
Figure 5 Non-catalytic functions of FAK and PAK kinases in cell motility and survival. (A) FAK mediated translocation of paxillin to the cell
membrane initiates activation of the JNK pathway and cell motility by recruiting the Rac/Cdc42 exchange factor PIX. (B) FAK and the related kinase
Pyk2 can translocate to the nucleus where they bind p53 and Mdm2 to induce p53 ubiquitination and degradation, promoting cell proliferation
and survival. (C) PAK1 regulates focal adhesion dynamics by promoting paxillin recruitment to focal adhesions. (D) Chemotactic cytokines via Gb/g
proteins induce a positive feedback activation of Cdc42 by activating Rac, which in turn activates the Rac/Cdc42 exchange factor PIX. (E) PAK1
scaffolds the activation of Akt1 by PDK1 at the cell membrane and coordinates the selective phosphorylation of downstream Akt1 substrates.
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responses. Similarly, PAK2 was recently described as reg-
ulating Cdc42-induced actin reorganization and spindle
orientation by directly binding to the b-PIX GEF [139].
Another important PAK target is Akt, which has a cen-
tral role in the regulation of metabolism, apoptosis, cell
migration and transformation [140]. Whereas some stu-
dies suggest that PAK might directly phosphorylate Akt at
the activating site S473 [141,142], a recent study demon-
strates that PAK can also facilitate Akt phosphorylation in
a kinase-independent manner [136] (Figure 5E). The
kinase domain of PAK1 directly interacts with Akt and
mediates its translocation to the plasma membrane, where
S473 can be phosphorylated by mTORC2 [143] or PAK
itself [141,142]. This step requires an activating conforma-
tional change of PAK induced by Rac binding, but no PAK
kinase activity per se.P A K 1a l s or e c r u i t sP D K 1 ,t h eA k t
T308 kinase [144], and this interaction is greatly facilitated
by growth factors [136]. Thus, PAK1 promotes Akt trans-
location to the plasma membrane and serves as a scaffold
that facilitates the interaction of PDK1 with Akt. Interest-
ingly, PAK1mediated Akt activation exhibits isoform selec-
tivity, affecting Akt1 responses more than Akt2, and in
addition biased Akt substrate selection [136]. Expression
of the N-terminal regulatory domain of PAK1, which
seems to interfere with the ability of PAK to recruit PDK1,
preferentially reduced the phosphorylation of nuclear Akt
substrates, such as FoxO3a, while the phosphorylation
levels of the cytosolic substrates S6K, BAD and GSK3
remained intact. This suggests that PAK scaffolding might
direct the substrate specificity of Akt or limit its accessibil-
ity towards a subset of its substrates or both. It remains
unclear, however, how the PAK dependent PDK1-Akt
complex, which is formed at the cell membrane, affects
nuclear Akt substrates. On the other hand, both Akt and
PDK1 participate in PAK1 regulation. Akt can phosphory-
late and partially activate PAK1 [145], and PDK1 was
shown to activate PAK1 by direct phosphorylation in the
activation loop [146]. Thus, kinases seem to be able to
mutually activate each other in the PAK1 scaffolded
PDK1-Akt complex by positive feedback loops, which is
likely to result in a switchlike, digital signal output [147].
Members of the constitutively active group II PAK
family (PAKs 4-6) also have been shown to mediate part
of their effects via kinase-independent functions. PAK4
protects cells from apoptosis induced by death receptors
in a kinase-independent manner by interfering with the
recruitment and activation of caspase 8 to the death
domains in the receptors [148]. In addition, PAK4 is
needed for the efficient activation of survival pathways in
response to TNFa by facilitating the binding of the scaf-
fold protein TRADD to the activated TNFa receptor
partly through a kinase-independent mechanism [149].
The role for PAK4 in regulating prosurvival pathways in a
kinase-independent manner is a new function for this pro-
tein, and may help explaining its role in tumorigenesis
[150,151] and development [152].
Kinase independent regulation of phosphoinositide
signaling pathways
Phosphatidylinositol 3-kinases (PI3K)
PI3Ks are intracellular lipid kinases that phosphorylate the
3’-hydroxyl group of phosphatidylinositol and phosphoi-
nositides [153]. Their action is counteracted by the Phos-
phatase and tensin homolog (PTEN) phosphatase, which
is frequently altered in cancer [154,155]. PI3Ks are divided
into three classes according to their substrates specificity
and sequence homology. Class I PI3Ks are activated by
surface receptors and preferentially generate phosphatidy-
linositol-3,4,5-trisphosphate (PIP3) from phosphatidylino-
sitol-4,5-bisphosphate (PI4,5P2) [153]. Class I PI3Ks are
heterodimers consisting of a catalytic and a regulatory
subunit. Catalytic domains p110a, p110b or p110δ form
together with p85, p55 or p50 regulatory domains class IA
PI3Ks. Class IB PI3K consists of the catalytic p110g and
regulatory p101 or p84/p87 subunit [153,156]. Despite the
fact that all class I PI3Ks generate PIP3, their simultaneous
expression suggests that some of their functions might be
not redundant. Indeed, a comprehensive study done by
Knight and colleagues revealed specific functions of class
PI3Ks in insulin signalling [157]. For instance, p110b is
important for maintaining the PIP3 pool in unstimulated
myotubes and balancing PTEN, a lipid phosphatase, activ-
ity thus setting a threshold for Akt activation. It is also
required for Akt activation in a response to lysophosphati-
dic acid (LPA) stimulation [158-160]. However, p110b is
dispensable for Akt activation induced by insulin, since
p110a is the major PIP2 kinase in this signalling pathway
[157]. Surprisingly, in some cases the phenotype observed
after catalytic subunit knockdown was much more severe
than the phenotype induced by saturating concentrations
of an isoform-specific chemical inhibitor [161,162]. This
suggests the possibility that catalytic subunits of PI3 kinase
might fulfil other, kinase independent functions in cellular
regulation. These, kinase-independent functions of PI3Ks
were elegantly validated by obtaining knock-in homozy-
gote mice bearing kinase dead mutants of PI3 kinase.
Importantly, the phenotype of these knock-in mice was
markedly different and less severe than the corresponding
knockout phenotypes [163]. Here, we discuss some speci-
fic examples of non-catalytic PI3 kinase functions.
p110b p110b can be activated by growth factors and
insulin. Several recent studies identified both kinase-
dependent and independent roles for this isoform
[157-159]. p110b is dispensable for Akt phosphorylation
induced by insulin, IGF-1 (Insulin-like Growth Factor),
Epidermal Growth Factor (EGF) or Platelet-derived
Growth Factor (PDGF) stimulation [158]. However, the
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mediated by lysophosphatidic acid (LPA) [158,159], and a
lack of catalytically active p110b protected mice from
breast cancer development induced by ERBB2 or from
prostate tumour development driven by loss of PTEN
[158,159]. The latter phenomenon can be attributed to a
basal catalytic activity of p110b and its balancing effect
towards PTEN activity [157]. On the other hand, kinase-
independent functions of p110b are crucial for several
physiological processes, including embryonic develop-
ment. Mice homozygotic for kinase-dead p110b develop
normally and survive to adulthood, except growth retar-
dation and developing a mild insulin resistance with age
[158], whereas the p110b knockout leads to embryonic
lethality in mice [164]. Further, catalytically inactive
p110b facilitates endocytosis in a rate similar to the wild
type p110b subunit, as indicated by transferrin and EGFR
uptake [158,159].p110b, unlike p110a,c a nb ef o u n di n
the nucleus [165], and recent studies revealed kinase-
dependent and independent functions of p110b in DNA
replication and repair [161,162]. In response to DNA
double strand breaks (DSBs) PI3Kb participates in sen-
sing the damage by mediating the binding of the DNA
damage sensor protein Nbs1to DSBs and the recruitment
of the full MRN (Mre11, Rad50, Nbs1) complex, which
then activates the DNA damage kinase ATM. The assem-
bly of this complex does not require PI3Kb catalytic activ-
ity, although kinase competent PI3Kb is more efficient
[161]. ATM then recruits the replication protein A (RPA)
complex and the ATR kinase. ATR and ATM are check-
point kinases which halt the cell cycle until the DNA
damage is repaired by the Rad51 recombinase (Figure 6A).
The defective DNA repair in p110b knockout cells leads
to genomic instability and chromosomal aberrations.
However, cells expressing kinase-dead p110b were predo-
minantly normal, clearly demonstrating that kinase-inde-
pendent functions of p110b are sufficient to upkeep
radiation-induced DNA repair [161].
In DNA replication the catalytic activity of p110b is
required for the efficient progress of the replication fork
[162]. p110b regulate PCNA (proliferating cell nuclear
antigen) binding to the DNA and p21
waf/cip phosphoryla-
tion. Surprisingly, the downregulation of p110b by shRNA
revealed also kinase-independent function of p110b.
p110b contributes to nuclear localization of Akt indepen-
dently of its catalytic activity. In addition, the ability of
p110b to bind PCNA and to facilitate its chromatin load-
ing is at least partially independent of the p110b catalytic
activity [162]. This study provides us with a molecular
mechanism of p110b’s kinase-independent role in cell
cycle previously demonstrated by BrdU incorporation
assay [159].
p110g Unlike the ubiquitously expressed p110a and
p110b subunits, p110g expression is limited to certain
tissues, including the hematopoietic system, endothelial
cells, and cardiomyocytes [166,167].
Ischemia-induced angiogenesis is dependent on the
PI3Kg subunit. However, mice expressing a kinase-dead
p110g mutant entertain a normal reparative neovasculari-
zation, as indicated by capillary density and blood flow
recovery. In detail, p110g has a kinase-independent func-
tion in endothelial progenitor cells (EPC) migration
induced by the chemokine Stromal-cell Derived Factor 1
(SDF-1), while EPC incorporation into vascular networks
requires the catalytic activity of p110g [168].
Another study described the protective role of PI3Kg in
myocardial ischemia and reperfusion (M I/R) injury. PI3Kg
knockout mice had massive immediate and long-term
Figure 6 PI3K signaling independent of catalytic activity. (A) PI3Kb binding to DNA double strand breaks (DSBs) recruits DNA damage
sensor and DNA repair enzymes. (B) PI3Kg comprising of the p110g and p87, catalytic and regulatory subunits, serves as scaffold for a Protein
Kinase A (PKA) and phosphodiesterase 3B (PDE3B) containing protein complex that regulates b-adrenergic receptor internalization and muscle
contractility in cardiomyocytes.
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T h ec a r d i o p r o t e c t i v er o l eo fp 1 1 0 g did not require its
kinase activity, since catalytically inactive p110g knock-in
mice had phenotypes similar to their wild-type littermates
[169].
Of interest, PI3Kg knockout cardiomyocytes showed a
higher contractility, and PI3Kg was shown to act as a nega-
tive regulator of contractility [170]. In cardiac hypertrophy
models using chronic pressure overload caused by trans-
v e r s ea o r t i cc o n s t r i c t ion (TAC) [171,172] PI3Kg activity
and expression levels were upregulated in the heart
[173,174]. PI3Kg knockout mice develop severe myocardial
damage in response to TAC surgery suggesting that PI3Kg
has a protective role. Mice expressing kinase-dead PI3Kg
had preserved myocardial function a week after TAC,
despite the lack of Akt and Erk activation in a response to
TAC-induced mechanical stress. This can be explained by
an ability of PI3Kg to form a complex with phosphodies-
terase 3B (PDE3B) independently of its kinase activity.
PDE3B is associated with PI3Kg in a constitutive manner
and this interaction is required for PDE3B phosphodiester-
ase catalytic activity [174]. Furthermore, the PI3K regula-
tory subunit, p87 but not p101 undergoes a physical
interaction with PDE3B [175]. Thereby, PI3Kg helps to
maintain cAMP levels and thus prevents tissue necrosis
independently of its kinase activity [174].
A subsequent study revealed the molecular mechanism
of how cAMP levels in cardiomyocytes are regulated by
PI3K independently of the PIP3 levels [176] (Figure 6B).
While the regulatory subunit of PI3K, p87, directly binds
phosphodiesterase 3B (PDE3B), the catalytic subunit,
p110g, binds Protein Kinase A (PKA). cAMP, regenerated
in cardiomyocytes upon Β-adrenergic receptor stimulation,
leads to activation of PKA. Catalytically active PKA phos-
phorylates and activates PDE3B, thus providing a negative
feedback regulation. In this system, PI3K serves as an
anchoring protein, bringing PKA in proximity to its sub-
strate. In addition, PKA phosphorylates p110g and inhibits
its kinase activity, thus decreasing the PIP3 levels. Since
PIP3 is required for b-adrenergic receptor internalization,
PKA helps to maintain receptor levels on the plasma
membrane. In failing hearts, PI3K kinase activity is ele-
vated, partially as a result of high expression levels of
p110g. In addition to that, the expression level of the regu-
latory subunit p101 is elevated as well. Since this subunit
does not interact with PKA, the p110g bound to p101
remains constitutively active leading to b-adrenergic
receptor downregulation and heart failure [176].
PDK1
Phosphoinositide-Dependent Kinase 1 (PDK1) is a major
regulator of at least 23 AGC kinases. Surprisingly, PDK1
is constitutively active and cell stimulation does not
change its phosphorylation status at the activation loop
or the kinase activity [177,178]. PDK1 mediates its own
phosphorylation, thus explaining why the protein
expressed in bacteria is phosphorylated and fully active;
most likely this phosphorylation proceeds by a trans-
molecular mechanism [178]. In the PI3K signalling path-
way PDK1 participates in Akt activation. Upon PIP3
accumulation mediated by PI3Ks Akt is recruited to the
plasma membrane via its PH domain binding to PIP3 or
by association with PAK1 as discussed above. PDK1then
phosphorylates Akt at the activation loop (T308)
[177,178]. PDK1 itself contains a PH domain, however it
remains controversial whether cell stimulation affects its
localization within the cell [179,180].
Recent studies suggested that PDK1 has additional,
kinase-independent functions in the coordination of sig-
nalling pathways [181,182]. For instance, PDK1 is involved
in activating the small G protein Ral [182]. Ral is a small
GTPase whose activation is mediated by a Ral specific
GEF, Ral-GDS (Ral-Guanine nucleotide Dissociation Sti-
mulator) [183]. Besides Raf kinases and PI3K, Ral-GDS is
one of the three classic Ras effectors [184,185]. Ras contri-
butes to Ral activation by bringing the Ral-GDS proximate
to its substrate, but is not sufficient for the full catalytic
activation of Ral-GDS [186]. Therefore, an additional step
is required for optimal Ral activation, and PDK1
was demonstrated to fulfil this complementary role [182]
(Figure 7A). PDK1 binds the N-terminal region of Ral-
GDS and relieves it from inhibition. This N-terminal part
of Ral-GDS was shown to possess autoinhibitory activity
and Ral-GDS lacking this region has higher basal GEF
activity. This function of PDK1 is kinase-independent,
since a kinase-dead PDK1 mutant performed indistin-
guishably from wild type PDK1. Moreover, PDK1 lacking
50 amino acids in its regulatory domain did not enhance
Ral-GDS activity, but was able to phosphorylate Akt at
T308. These results demonstrate a clear distinction
between kinase-dependent and -independent functions of
PDK1 in response to growth factor stimulation [182].
Another example of PDK1 acting as a scaffolding protein
was described in T-cells, where PDK1 takes part in NFB
activation upon T-cell receptor (TCR) activation. PDK1
phosphorylates and recruits PKCθ to the plasma mem-
brane and also recruits the CARMA1- Bcl10 -MALT1
complex, bringing it proximal to the PKCθ-bound IB
kinase (IKK) complex, which consists of two kinases IKKa/
b and a scaffolding protein IKKg or NEMO. The MALT1
complex ubiquitinates NEMO leading to the activation of
IKKa/b and phosphorylation of IB. Phosphorylation tar-
gets IB for degradation thereby releasing NFBt ot h e
nucleus where it activates the expression of survival and
proliferation genes. Thus, PDK1, in addition of being the
PKCθ kinase, also serves as a nucleating factor that assem-
bles a multi-protein complex mediating NFB activation
downstream of TCR [181]. This multi-protein complex
might also facilitate the PKCθ-mediated phosphorylation of
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MALT1. This event is absolutely required for TCR-
induced NFB activation [187]. Therefore, PDK1 fulfils a
dual role operating both as a kinase and as a scaffolding
protein that promotes formation of a multi-protein com-
plex required for NFB activation in T cells.
Mammalian target of rapamycin (mTOR)
mTOR kinase is found in two distinct multi-protein com-
plexes with different substrate specificity, mTOR complex
1 (mTORC1) and mTORC2, that contain Raptor or Rictor
as function defining elements, respectively. mTORC1 acti-
vation is mediated by Akt downstream to PI3K, whereas
rather little is known about mTORC2 regulation [188].
The ability of mTORC1 to phosphorylate its downstream
targets can be negatively regulated by rapamycin. It is
unclear whether rapamycin affects mTOR kinase activity
or prevents mTORC1 from interacting with its substrates,
since rapamycin-bound mTOR complex 1 can still phos-
phorylate some of its substrates or autophosphorylate
under certain conditions [189-191]. Therefore, the ability
of rapamycin to block a particular signaling event does not
indicate that this event necessarily requires the catalytic
activity of mTORC1.
Rapamycin prevented the differentiation of C2C12
mouse myoblast cells into skeletal muscle cells. This
inhibition could be rescued by a rapamycin-resistant
mTOR mutant [192]. Surprisingly, mTOR bearing an
additional mutation that abolishes its kinase activity
could also mediate cell differentiation. Of note, during
cell differentiation the mTOR expression levels are
upregulated on a posttranscriptional level, but no upre-
gulation of mTOR kinase activity could be observed
[192]. Another study performed in C2C12 cells demon-
s t r a t e dt h a tm T O Rm e d i a t e dm u s c l ec e l ld i f f e r e n t i a t i o n
did require its kinase activity [193]. The reason for this
discrepancy is unclear.
However, subsequent studies, performed both in in vivo
and in in vitro models, support the kinase independent
function of mTOR in muscle cell differentiation and main-
tenance, and provide a molecular explanation. miRNA-
125b expressed in skeletal muscle cells negatively regulates
muscle differentiation and injury-induced muscle regen-
eration by downregulating IGF-II, which is required for
this process. mTOR negatively regulates miRNA-125b
expression in repairing tissue, and that this mTOR func-
tion does not require its catalytic activity [194]. The condi-
tional knockout of mTOR in muscle cells led to severe
myopathy and premature death in mice. Among other
changes induced by the mTOR knockout, cells lacking
mTOR, but not raptor or rictor, had decreased expression
levels of dystrophin. Dystrophin expression in muscle cells
is regulated by mTOR on the transcriptional level inde-
pendently of its kinase activity. Chromatin immunopreci-
pitation (ChIP) experiments indicated that mTOR binds
to the dystrophin promoter [195]. Thus, this study indi-
cates a kinase independent, but also raptor and rictor
independent functions of mTOR in transcriptional regula-
tion [195].
Pseudokinases
Interestingly, 48 out of the reported 518 kinases in the
human genome seem to have lost their kinase activity alto-
gether due to mutations of critical amino acids in their
kinase domains thought to be required for catalytic func-
tions. These so-called pseudokinases still have important
catalysis-independent functions, e.g. as scaffolding proteins
[59,196]. It is beyond the scope of this review to discuss
the function of pseudokinases in detail, and we refer
Figure 7 Catalytic-independent functions of PDK1. (A) PDK1 induces activation of the Ral small G protein by binding to and relieving its GEF,
Ral-GDS from the autoinhibitory conformation. (B) PDK1 mediates NFB activation in T-cells by serving as a scaffold that brings CARMA1-BCL10-
MALT1complex proximal to the PKCq-bound IKK complex, thus allowing ubiquitination of NEMO (IKKg). This leads to activation of IKKs,
phosphorylation and subsequent degradation of the NFB inhibitor IB and release of active NFB into the nucleus.
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[46,196,197]. Within this review we only briefly discuss
recent results indicating that the distinction between
kinases and pseudokinases may be blurred. Pseudokinases
seem to have developed from standard kinases by muta-
tion of a few key catalytic residues while preserving the
general primary and tertiary sequence organisation of the
classic well-conserved kinase domains. Thus, the substrate
binding properties of the kinase domains have evolved to
become their main functions. This transition, however,
seems to be gradual, and there is an increasing number of
examples where pseudokinases can acquire kinase activity
under certain conditions.
In the case of the Wnk kinase family, the general struc-
tural conservation of the kinase domain allows for a
slightly modified catalytic mechanism despite lacking key
catalytic residues characteristic for classic kinase domains
[198-200]. Another example of a pseudokinase that uses
an unconventional catalytic mechanism is the EGF recep-
tor family member ErbB3/HER3. The traditional view was
that ErbB3 lacks kinase activity but is phosphorylated and
transactivated via dimerization with the active kinase
ErbB2/HER2 [201,202]. Recent structural and molecular
dynamics based modelling studies showed that the ErbB3
pseudokinase domain uses an alternative phosphotransfer
mechanism to transautophosphorylate its intracellular
region [203]. These recent results might suggest, that
pseudokinases might be more active than anticipated by
using alternative catalytic mechanisms.
Interestingly, in some cases these unorthodox catalytic
a c t i v i t i e sm a yr e l yo nv e r ys p e c i f i ca l l o s t e r i ca c t i v a t i o n
mechanisms exerted by the substrates and associated
modulator proteins. A recent example is the scaffold
KSR2, member of the extended Raf family and well known
for its role in coordinating Raf-MEK-ERK complexes
[59,204], was shown to possess catalytic activity towards
MEK [205]. This activity was dependent on Raf-1 binding
to KSR2 and due to an allosteric activation mechanism.
The KSR2 targeted phosphorylation sites in MEK were dif-
ferent from the known regulatory sites suggesting that the
combination of a scaffold with the allosteric activation of a
pseudokinase domain may confer exquisite substrate spe-
cificity. On the other hand, the observed KSR2 mediated
MEK phosphorylation was of very low stoichiometry and
its physiological relevance remains to be tested.
Technical notes
Most kinases mentioned in this review were first identified
as enzymes, and only later additional functional functions
were identified. Whereas the catalytic activity of a kinase is
relatively easy to test, assaying for kinase-independent func-
tions is more far more difficult. It still is challenging
to determine kinase-interacting partners, and more
importantly whether these protein-protein interactions
contribute to the regulation of signalling independently of
catalytic activity. In many studies kinase mutants lacking a
kinase domain or bearing kinase-inactivating mutations
were overexpressed, and the phenotype obtained was attrib-
uted to a non-catalytic activity of the protein. These studies
contributed much to our current understanding of kinase
activities in different systems. However, the massive overex-
pression of a mutated protein will change the stoichio-
metric ratios between interacting proteins and hence may
not accurately reflect physiological phenomena. Novel tech-
nologies, such as small interfering RNA or knockin mice,
allow creating a clean temporary or permanent background
where the contribution of any particular kinase can be
assessed without overexpression. In this case, the rescue of
a phenotype with a kinase-dead kinase can serve as a much
more reliable indication of non-catalytic kinase activities.
Conclusions
One of the clear functions of kinases within signalling net-
works is to receive signals from an upstream regulator and
to amplify it by phosphorylating multiple substrate mole-
cules. Any function independent of catalytic activity will
be governed by purely stoichiometric relationships and
will be lacking the amplification potential. However, while
losing the advantage of signal amplification this mechan-
ism might offer other advantages. Therefore, it is legiti-
mate to ask: Why do protein kinases have non-catalytic
functions? There are likely many more phosphorylation
sites than proteins [206,207] not only raising questions
about the functional roles of these phosphorylations, but
also about the specificity of protein kinases. In fact, the
specificity of protein kinases seems so poor that the
expansion of tyrosine kinases went hand in hand with a
reduction of the number of tyrosines in proteins [208].
Thus, is it the quest for specificity rather than catalytic
efficiency that rules the kinase world? The first call on spe-
cificity is the kinase domain itself and the range of sub-
strates it can interact with. The protein kinases that
essentially consist of a kinase domain only, such as
MAPKs, usually feature a large number of substrates and a
large number of scaffolding proteins that direct them to
selected substrates. In addition, their substrates have
developed dedicated docking domains [82]. In contrast,
large kinases with a complex domain structure, such as
the PI3Ks are often remarkably specific, and usually func-
tion as scaffolds themselves. A crucial finding was the exis-
tence of SH2 and SH3 interaction domains by Tony
Pawson’s group. Many kinases described above contain
multiple such protein-protein interaction domains, which
are crucial for both, catalytic and non-catalytic, functions
enabling them to act as scaffolds in addition to their cata-
lytic role [209,210].
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interactions, which can regulate the dynamic turnover of
protein complexes. Although an oversimplification, this
observation indicates that specificity is mainly achieved
by regulating protein interactions that determine the
binding of activators and substrates, subcellular localisa-
tion and dynamic changes of these conditions. In fact,
manipulating protein docking interactions can override
the intrinsic catalytic specificity of kinases [211]. There-
fore, non-catalytic functions may be paramount to ensure
the catalytic specificity of protein kinases. Many of the
examples discussed above support this view. Often the
cooperation between catalytic and non-catalytic kinase
functions is needed to cause the full and correct biologi-
cal effects. This design also affords maximum versatility
by embedding protein kinases into different protein com-
plexes in order to generate different signalling specifici-
ties. Pseudokinases may represent the extreme end of
this scale. They lack catalytic activity altogether or only
exhibit it under highly confined conditions depending on
allosteric activation by binding partners [197].
These mechanisms contribute to the specificity of protein
kinase action by providing mechanisms of ap r i o r isubstrate
discrimination. However, another and complementary way
to achieve specificity is to increase the signal to noise ratio
of protein kinase signalling. Again, non-catalytic functions
seem to be key. An example is provided by the observation
that tyrosine kinases often use SH2 domains, which dock to
phospho-tyrosines, to recognise substrates previously phos-
phorylated by themselves or other tyrosine kinases [212].
Many of the signalling complexes discussed above are
assembled via non-catalytic kinase functions, but involve
multiple positive feedback loops exerted by phosphoryla-
tion. The combination of non-catalytic protein complex
assembly and catalytic reinforcement of connections or
outputs generate a high fidelity filter [147] that can pro-
gram reliable biological responses.
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